
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/165444/publications.pdf Version: 2024-02-01



ALEONSO FASANO

#	Article	IF	CITATIONS
1	Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurology, The, 2015, 14, 625-639.	10.2	653
2	Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain, 2010, 133, 2664-2676.	7.6	367
3	Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurology, The, 2012, 11, 429-442.	10.2	343
4	Infection-Triggered Familial or Recurrent Cases of Acute Necrotizing Encephalopathy Caused by Mutations in a Component of the Nuclear Pore, RANBP2. American Journal of Human Genetics, 2009, 84, 44-51.	6.2	291
5	The role of small intestinal bacterial overgrowth in Parkinson's disease. Movement Disorders, 2013, 28, 1241-1249.	3.9	267
6	Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model Journal of Clinical Investigation, 1997, 99, 1158-1164.	8.2	236
7	Levodopaâ€induced dyskinesia in Parkinson disease: Current and evolving concepts. Annals of Neurology, 2018, 84, 797-811.	5.3	225
8	Falls in Parkinson's disease: A complex and evolving picture. Movement Disorders, 2017, 32, 1524-1536.	3.9	220
9	Axial disability and deep brain stimulation in patients with Parkinson disease. Nature Reviews Neurology, 2015, 11, 98-110.	10.1	208
10	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.1	194
11	"On―state freezing of gait in Parkinson disease. Neurology, 2012, 78, 454-457.	1.1	178
12	Programming Deep Brain Stimulation for Parkinson's Disease: The Toronto Western Hospital Algorithms. Brain Stimulation, 2016, 9, 425-437.	1.6	164
13	Physiology of freezing of gait. Annals of Neurology, 2016, 80, 644-659.	5.3	160
14	Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: From the advanced phase towards the late stage of the disease?. Parkinsonism and Related Disorders, 2014, 20, 376-381.	2.2	150
15	Prevalence of Small Intestinal Bacterial Overgrowth in Parkinson's Disease. Movement Disorders, 2011, 26, 889-892.	3.9	145
16	Outcomes from stereotactic surgery for essential tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 474-482.	1.9	141
17	Predicting optimal deep brain stimulation parameters for Parkinson's disease using functional MRI and machine learning. Nature Communications, 2021, 12, 3043.	12.8	130
18	Lesions causing freezing of gait localize to a cerebellar functional network. Annals of Neurology, 2017, 81, 129-141.	5.3	129

#	Article	IF	CITATIONS
19	Focused ultrasound thalamotomy location determines clinical benefits in patients with essential tremor. Brain, 2018, 141, 3405-3414.	7.6	129
20	<scp>COVID</scp> â€19 in Parkinson's Disease Patients Living in Lombardy, Italy. Movement Disorders, 2020, 35, 1089-1093.	3.9	129
21	Evolving concepts on bradykinesia. Brain, 2020, 143, 727-750.	7.6	120
22	Systematic review of hardware-related complications of Deep Brain Stimulation: Do new indications pose an increased risk?. Brain Stimulation, 2017, 10, 967-976.	1.6	118
23	Gait ataxia in essential tremor is differentially modulated by thalamic stimulation. Brain, 2010, 133, 3635-3648.	7.6	117
24	Management of status dystonicus: Our experience and review of the literature. Movement Disorders, 2007, 22, 963-968.	3.9	115
25	Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Movement Disorders, 2011, 26, 313-319.	3.9	111
26	The treatment of dystonic tremor: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 759-769.	1.9	105
27	Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.	1.1	103
28	Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Movement Disorders, 2012, 27, 559-561.	3.9	102
29	Modulation of gait coordination by subthalamic stimulation improves freezing of gait. Movement Disorders, 2011, 26, 844-851.	3.9	94
30	Status dystonicus: Predictors of outcome and progression patterns of underlying disease. Movement Disorders, 2012, 27, 783-788.	3.9	94
31	Compensation Strategies for Gait Impairments in Parkinson Disease. JAMA Neurology, 2019, 76, 718.	9.0	94
32	Psychogenic facial movement disorders: Clinical features and associated conditions. Movement Disorders, 2012, 27, 1544-1551.	3.9	93
33	Integrated safety of levodopaâ€carbidopa intestinal gel from prospective clinical trials. Movement Disorders, 2016, 31, 538-546.	3.9	91
34	Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson's disease. Brain, 2018, 141, 177-190.	7.6	91
35	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The <scp>COVID</scp> â€19 Experience. Movement Disorders Clinical Practice, 2020, 7, 361-372.	1.5	91
36	Neuroimaging of Freezing of Gait. Journal of Parkinson's Disease, 2015, 5, 241-254.	2.8	90

#	Article	IF	CITATIONS
37	Neurological disorders of gait, balance and posture: a sign-based approach. Nature Reviews Neurology, 2018, 14, 183-189.	10.1	88
38	Effect of shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo Gut, 1997, 40, 505-511.	12.1	86
39	The <scp>C</scp> ontursi <scp>F</scp> amily 20 <scp>Y</scp> ears <scp>L</scp> ater: <scp>I</scp> ntrafamilial <scp>P</scp> henotypic <scp>V</scp> ariability of the <scp><i>SNCA</i></scp> p. <scp>A</scp> 53T <scp>M</scp> utation. Movement Disorders, 2016, 31, 257-258.	3.9	86
40	Programming Deep Brain Stimulation for Tremor and Dystonia: The Toronto Western Hospital Algorithms. Brain Stimulation, 2016, 9, 438-452.	1.6	86
41	Insights into pathophysiology of punding reveal possible treatment strategies. Molecular Psychiatry, 2010, 15, 560-573.	7.9	83
42	The neurobiology of falls. Neurological Sciences, 2012, 33, 1215-1223.	1.9	83
43	Facial Emotion Recognition and Expression in Parkinson's Disease: An Emotional Mirror Mechanism?. PLoS ONE, 2017, 12, e0169110.	2.5	83
44	Anhedonia in Parkinson's disease patients with and without pathological gambling: A case-control study. Psychiatry Research, 2014, 215, 448-452.	3.3	81
45	Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. Journal of Neurosurgery, 2018, 128, 1199-1213.	1.6	81
46	MRI-guided focused ultrasound thalamotomy in non-ET tremor syndromes. Neurology, 2017, 89, 771-775.	1.1	79
47	Novel Approaches for Oral Delivery of Macromolecules. Journal of Pharmaceutical Sciences, 1998, 87, 1351-1356.	3.3	77
48	Deep brain stimulation for movement disorders. Current Opinion in Neurology, 2015, 28, 423-436.	3.6	76
49	Cocaine addiction: From habits to stereotypical-repetitive behaviors and punding. Drug and Alcohol Dependence, 2008, 96, 178-182.	3.2	75
50	Where have all the American celiacs gone?. Acta Paediatrica, International Journal of Paediatrics, 1996, 85, 20-24.	1.5	74
51	GPiâ€DBS in Huntington's disease: Results on motor function and cognition in a 72â€yearâ€old case. Movement Disorders, 2008, 23, 1289-1292.	3.9	74
52	Postural control and freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 24, 107-112.	2.2	74
53	Essential pitfalls in "essential―tremor. Movement Disorders, 2017, 32, 325-331.	3.9	74
54	Characterizing advanced Parkinson's disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology, 2019, 19, 50.	1.8	74

#	Article	IF	CITATIONS
55	The prevalence and clinical characteristics of punding in Parkinson's disease. Movement Disorders, 2011, 26, 578-586.	3.9	73
56	Pisa syndrome in Parkinson disease. Neurology, 2015, 85, 1769-1779.	1.1	72
57	Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy. Annals of Neurology, 2021, 89, 426-443.	5.3	68
58	Fifteen-Year Experience in Treating Blepharospasm with Botox or Dysport: Same Toxin, Two Drugs. Neurotoxicity Research, 2009, 15, 224-231.	2.7	66
59	Gait patterns in parkinsonian patients with or without mild cognitive impairment. Movement Disorders, 2012, 27, 1536-1543.	3.9	66
60	Temporal discrimination in patients with dystonia and tremor and patients with essential tremor. Neurology, 2013, 80, 76-84.	1.1	65
61	The overlap between Essential tremor and Parkinson disease. Parkinsonism and Related Disorders, 2018, 46, S101-S104.	2.2	65
62	Parkinson's Disease and the COVID-19 Pandemic. Journal of Parkinson's Disease, 2021, 11, 431-444.	2.8	65
63	Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia. Canadian Journal of Neurological Sciences, 2016, 43, 462-471.	0.5	63
64	Bradykinesia in early and advanced Parkinson's disease. Journal of the Neurological Sciences, 2016, 369, 286-291.	0.6	63
65	Tremor habituation to deep brain stimulation: Underlying mechanisms and solutions. Movement Disorders, 2019, 34, 1761-1773.	3.9	63
66	Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 134-137.	2.2	63
67	Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Movement Disorders, 2016, 31, 1785-1795.	3.9	62
68	The relevance of skull density ratio in selecting candidates for transcranial MR-guided focused ultrasound. Journal of Neurosurgery, 2020, 132, 1785-1791.	1.6	62
69	Update on Current Technologies for Deep Brain Stimulation in Parkinson's Disease. Journal of Movement Disorders, 2020, 13, 185-198.	1.3	62
70	Lateral trunk flexion in Parkinson's disease: EMG features disclose two different underlying pathophysiological mechanisms. Journal of Neurology, 2011, 258, 740-745.	3.6	61
71	Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: Clinical features and mechanisms. Parkinsonism and Related Disorders, 2013, 19, 1004-1008.	2.2	61
72	Impulsive-compulsive behaviors in <i>parkin</i> -associated Parkinson disease. Neurology, 2016, 87, 1436-1441.	1.1	61

#	Article	IF	CITATIONS
73	Diagnostic agreement in patients with psychogenic movement disorders. Movement Disorders, 2012, 27, 548-552.	3.9	60
74	Pisa syndrome in Parkinson's disease: an electrophysiological and imaging study. Journal of Neurology, 2013, 260, 2138-2148.	3.6	59
75	Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?. Movement Disorders, 2016, 31, 962-967.	3.9	59
76	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. Neurology, 2014, 82, 2250-2251.	1.1	56
77	Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease. JAMA Network Open, 2019, 2, e187800.	5.9	54
78	Management of punding in Parkinson's disease: an open-label prospective study. Journal of Neurology, 2011, 258, 656-660.	3.6	53
79	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. Parkinsonism and Related Disorders, 2018, 56, 109-110.	2.2	53
80	Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. European Review for Medical and Pharmacological Sciences, 2012, 16, 79-89.	0.7	53
81	Aceruloplasminemia: A novel mutation in a family with marked phenotypic variability. Movement Disorders, 2008, 23, 751-755.	3.9	52
82	Reduced facial expressiveness in Parkinson's disease: A pure motor disorder?. Journal of the Neurological Sciences, 2015, 358, 125-130.	0.6	52
83	Pallidal deep brain stimulation modulates cortical excitability and plasticity. Annals of Neurology, 2018, 83, 352-362.	5.3	51
84	Functional MRI Safety and Artifacts during Deep Brain Stimulation: Experience in 102 Patients. Radiology, 2019, 293, 174-183.	7.3	51
85	Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (<scp>BESTâ€FUS</scp> Phase 2 Trial). Movement Disorders, 2021, 36, 2653-2662.	3.9	51
86	The Long-term Effect of Tetrabenazine in the Management of Huntington Disease. Clinical Neuropharmacology, 2008, 31, 313-318.	0.7	50
87	Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy. Cortex, 2013, 49, 948-960.	2.4	50
88	Tetrabenazine. Expert Opinion on Pharmacotherapy, 2009, 10, 2883-2896.	1.8	49
89	Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1937-1948.	6.4	49
90	Effects of subthalamic nucleus deep brain stimulation and l-dopa on blinking in Parkinson's disease. Experimental Neurology, 2012, 235, 265-272.	4.1	49

#	Article	IF	CITATIONS
91	Low-frequency Subthalamic Stimulation in Parkinson's Disease: Long-term Outcome and Predictors. Brain Stimulation, 2016, 9, 774-779.	1.6	49
92	Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism and Related Disorders, 2018, 52, 1-5.	2.2	49
93	Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 426-433.	1.9	49
94	Unusual tremor syndromes: know in order to recognise. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1191-1203.	1.9	48
95	Taste performance in Parkinson's disease. Journal of Neural Transmission, 2014, 121, 119-122.	2.8	46
96	Analysis of blink rate in patients with blepharospasm. Movement Disorders, 2006, 21, 1225-1229.	3.9	45
97	Targeting of the Subthalamic Nucleus for Deep Brain Stimulation: A Survey Among Parkinson Disease Specialists. World Neurosurgery, 2017, 99, 41-46.	1.3	45
98	Predictors of deep brain stimulation outcome in tremor patients. Brain Stimulation, 2018, 11, 592-599.	1.6	43
99	Taste in Parkinson's disease. Journal of Neurology, 2015, 262, 806-813.	3.6	41
100	Split-belt locomotion in Parkinson's disease links asymmetry, dyscoordination and sequence effect. Gait and Posture, 2016, 48, 6-12.	1.4	41
101	Imaging alone versus microelectrode recording–guided targeting of the STN in patients with Parkinson's disease. Journal of Neurosurgery, 2019, 130, 1847-1852.	1.6	41
102	Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. Tremor and Other Hyperkinetic Movements, 2020, 7, 462.	2.0	41
103	On the (Nonâ€)equivalency of monopolar and bipolar settings for deep brain stimulation fMRI studies of Parkinson's disease patients. Journal of Magnetic Resonance Imaging, 2019, 49, 1736-1749.	3.4	40
104	Deep Brain Stimulation in Rare Inherited Dystonias. Brain Stimulation, 2016, 9, 905-910.	1.6	39
105	Outcome predictors, efficacy and safety of Botox and Dysport in the longâ€ŧerm treatment of hemifacial spasm. European Journal of Neurology, 2009, 16, 392-398.	3.3	38
106	Structural brain changes following subthalamic nucleus deep brain stimulation in Parkinson's disease. Movement Disorders, 2016, 31, 1423-1425.	3.9	38
107	Rethinking status dystonicus. Movement Disorders, 2017, 32, 1667-1676.	3.9	38
108	Diagnostic criteria for camptocormia in Parkinson's disease: A consensus-based proposal. Parkinsonism and Related Disorders, 2018, 53, 53-57.	2.2	38

#	Article	IF	CITATIONS
109	Four-week trunk-specific exercise program decreases forward trunk flexion in Parkinson's disease: A single-blinded, randomized controlled trial. Parkinsonism and Related Disorders, 2019, 64, 268-274.	2.2	38
110	Non-DYT1 early-onset primary torsion dystonia: Comparison with DYT1 phenotype and review of the literature. Movement Disorders, 2006, 21, 1411-1418.	3.9	37
111	What is "essential―about essential tremor? A diagnostic placeholder. Movement Disorders, 2018, 33, 58-61.	3.9	37
112	Current Directions in Deep Brain Stimulation for Parkinson's Disease—Directing Current to Maximize Clinical Benefit. Neurology and Therapy, 2020, 9, 25-41.	3.2	37
113	Reversible Pisa syndrome in patients with Parkinson's disease on rasagiline therapy. Movement Disorders, 2011, 26, 2578-2580.	3.9	36
114	Therapeutic advances in tremor. Movement Disorders, 2015, 30, 1557-1565.	3.9	36
115	Magnetic resonance–guided focused ultrasound thalamotomy for treatment of essential tremor: A 2â€year outcome study. Movement Disorders, 2018, 33, 1647-1650.	3.9	36
116	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. Movement Disorders Clinical Practice, 2019, 6, 576-585.	1.5	36
117	Cellular microbiology: can we learn cell physiology from microorganisms?. American Journal of Physiology - Cell Physiology, 1999, 276, C765-C776.	4.6	35
118	Punding and computer addiction in Parkinson's disease. Movement Disorders, 2006, 21, 1217-1218.	3.9	35
119	Movement disorders in multiple sclerosis: causal or coincidental association?. Multiple Sclerosis Journal, 2008, 14, 1284-1287.	3.0	35
120	The effect of dexmedetomidine on the firing properties of <scp>STN</scp> neurons in Parkinson's disease. European Journal of Neuroscience, 2015, 42, 2070-2077.	2.6	35
121	High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease. Movement Disorders, 2008, 23, 1916-1919.	3.9	34
122	Magnetic Resonance Imaging–Guided Focused Ultrasound Thalamotomy in Parkinson Tremor: Reoperation After Benefit Decay. Movement Disorders, 2018, 33, 848-849.	3.9	34
123	Deep Brain Stimulation in Patients With Mutations in Parkinson's Disease–Related Genes: A Systematic Review. Movement Disorders Clinical Practice, 2019, 6, 359-368.	1.5	34
124	Multimodal MRI for MRgFUS in essential tremor: post-treatment radiological markers of clinical outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 921-927.	1.9	34
125	A Wearable Proprioceptive Stabilizer (Equistasi®) for Rehabilitation of Postural Instability in Parkinson's Disease: A Phase II Randomized Double-Blind, Double-Dummy, Controlled Study. PLoS ONE, 2014, 9, e112065.	2.5	33
126	Homotoxicological remedies versus desmopressin versus placebo in the treatment of enuresis: a randomised, double-blind, controlled trial. Pediatric Nephrology, 2008, 23, 269-274.	1.7	32

#	Article	IF	CITATIONS
127	Adult motor phenotype differentiates Dravet syndrome from Lennoxâ€Gastaut syndrome and links <i><scp>SCN</scp>1A</i> to early onset parkinsonian features. Epilepsia, 2017, 58, e44-e48.	5.1	32
128	Interleaving Stimulation in Parkinson's Disease, Tremor, and Dystonia. Stereotactic and Functional Neurosurgery, 2018, 96, 379-391.	1.5	32
129	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. Journal of Neurology, 2018, 265, 2211-2220.	3.6	32
130	Modulation of Intestinal Permeability: An Innovative Method of Oral Drug Delivery for the Treatment of Inherited and Acquired Human Diseases. Molecular Genetics and Metabolism, 1998, 64, 12-18.	1.1	31
131	Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1151-1160.	2.8	31
132	New neurosurgical approaches for tremor and Parkinson's disease. Current Opinion in Neurology, 2017, 30, 435-446.	3.6	31
133	Technology-based assessment of motor and nonmotor phenomena in Parkinson disease. Expert Review of Neurotherapeutics, 2018, 18, 825-845.	2.8	31
134	Thalamic deep brain stimulation for orthostatic tremor: A multicenter international registry. Movement Disorders, 2017, 32, 1240-1244.	3.9	30
135	Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity. Frontiers in Human Neuroscience, 2021, 15, 708481.	2.0	30
136	Treatment with botulinum toxin in a patient with myasthenia gravis and cervical dystonia. Neurology, 2005, 64, 2155-2156.	1.1	29
137	Alphaâ€synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees. Movement Disorders, 2013, 28, 813-817.	3.9	29
138	Functional facial and tongue movement disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 139, 353-365.	1.8	29
139	Small intestinal bacterial overgrowth in Parkinson's disease: TribulationsÂof a trial. Parkinsonism and Related Disorders, 2018, 54, 110-112.	2.2	29
140	Neuroimaging Technological Advancements for Targeting in Functional Neurosurgery. Current Neurology and Neuroscience Reports, 2019, 19, 42.	4.2	29
141	The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection. Neurology, 2021, 96, 664-676.	1.1	29
142	Unilateral Extradural Motor Cortex Stimulation Is Safe and Improves Parkinson Disease at 1 Year. Neurosurgery, 2012, 71, 815-825.	1.1	28
143	Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology. Frontiers in Neurology, 2014, 5, 49.	2.4	28
144	Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards. Parkinsonism and Related Disorders, 2015, 21, 1041-1048.	2.2	28

#	Article	IF	CITATIONS
145	Clinical neurophysiology of Parkinson's disease and parkinsonism. Clinical Neurophysiology Practice, 2022, 7, 201-227.	1.4	28
146	Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurological Sciences, 2012, 33, 261-267.	1.9	27
147	Somatosensory temporal discrimination in essential tremor and isolated head and voice tremors. Movement Disorders, 2015, 30, 822-827.	3.9	27
148	Balance Dysfunction in Parkinson's Disease: The Role of Posturography in Developing a Rehabilitation Program. Parkinson's Disease, 2015, 2015, 1-10.	1.1	27
149	Recent advances in Essential Tremor: Surgical treatment. Parkinsonism and Related Disorders, 2016, 22, S171-S175.	2.2	27
150	Teleâ€health for patients with deep brain stimulation: The experience of the Ontario Telemedicine Network. Movement Disorders, 2018, 33, 491-492.	3.9	27
151	Deep brain stimulation for pantothenate kinaseâ€associated neurodegeneration: A metaâ€analysis. Movement Disorders, 2019, 34, 264-273.	3.9	27
152	COVID-19 in Parkinson's disease: what holds the key?. Journal of Neurology, 2021, 268, 2666-2670.	3.6	27
153	Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus. Movement Disorders, 2020, 35, 1945-1954.	3.9	27
154	The combined treatment with orbital and pretarsal botulinum toxin injections in the management of poorly responsive blepharospasm. Neurological Sciences, 2014, 35, 397-400.	1.9	26
155	The FM/AM world is shaping the future of deep brain stimulation. Movement Disorders, 2014, 29, 161-163.	3.9	26
156	Deep Brain Stimulation Target Selection for Parkinson's Disease. Canadian Journal of Neurological Sciences, 2017, 44, 3-8.	0.5	26
157	Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis. Parkinsonism and Related Disorders, 2019, 62, 122-127.	2.2	26
158	Modulation of inhibitory plasticity in basal ganglia output nuclei of patients with Parkinson's disease. Neurobiology of Disease, 2019, 124, 46-56.	4.4	26
159	Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A <scp>1‥ear</scp> Prospective Trial. Movement Disorders, 2020, 35, 1082-1083.	3.9	26
160	Neurodegenerative <i>VPS41</i> variants inhibit HOPS function and mTORC1â€dependent TFEB/TFE3 regulation. EMBO Molecular Medicine, 2021, 13, e13258.	6.9	26
161	Functional disorders after COVID-19 vaccine fuel vaccination hesitancy. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 339-340.	1.9	26
162	Cellular Microbiology: How Enteric Pathogens Socialize with Their Intestinal Host. Journal of Pediatric Gastroenterology and Nutrition, 1998, 26, 520-532.	1.8	26

#	Article	IF	CITATIONS
163	Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. Tremor and Other Hyperkinetic Movements, 2017, 7, 462.	2.0	26
164	Lower limb joints kinematics in essential tremor and the effect of thalamic stimulation. Gait and Posture, 2012, 36, 187-193.	1.4	25
165	Unfreezing of gait in patients with Parkinson's disease. Lancet Neurology, The, 2015, 14, 675-677.	10.2	25
166	Working on asymmetry in Parkinson's disease: randomized, controlled pilot study. Neurological Sciences, 2015, 36, 1337-1343.	1.9	25
167	Gait Disorders. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1344-1382.	0.8	24
168	Freezing of gait in Parkinson's disease: The paradoxical interplay between gait and cognition. Parkinsonism and Related Disorders, 2014, 20, 824-829.	2.2	24
169	Effects of Deep Brain Stimulation on Postural Trunk Deformities: A Systematic Review. Movement Disorders Clinical Practice, 2019, 6, 627-638.	1.5	24
170	Soft signs in movement disorders: friends or foes?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 961-962.	1.9	24
171	Concomitant Medication Usage with <scp>Levodopa arbidopa</scp> Intestinal Gel: Results from the <scp>COSMOS</scp> Study. Movement Disorders, 2021, 36, 1853-1862.	3.9	24
172	Emerging concepts on bradykinesia in nonâ€parkinsonian conditions. European Journal of Neurology, 2021, 28, 2403-2422.	3.3	24
173	Infliximab monotherapy in Neuro-Behçet's disease: Four year follow-up in a long-standing case resistant to conventional therapies. Journal of Neuroimmunology, 2011, 239, 105-107.	2.3	23
174	Long-term effects of pedunculopontine nucleus stimulation for Pisa syndrome. Parkinsonism and Related Disorders, 2014, 20, 1445-1446.	2.2	23
175	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa–carbidopa intestinal gel infusion. Parkinsonism and Related Disorders, 2015, 21, 968-971.	2.2	23
176	24â€< scp>Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced <scp>P</scp> arkinson's disease. Movement Disorders, 2016, 31, 597-598.	3.9	23
177	Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation. Canadian Journal of Neurological Sciences, 2016, 43, 626-634.	0.5	22
178	Punding in non-demented Parkinson's disease patients: Relationship with psychiatric and addiction spectrum comorbidity. Journal of the Neurological Sciences, 2016, 362, 344-347.	0.6	22
179	Peripheral neuropathy as marker of severe Parkinson's disease phenotype. Movement Disorders, 2017, 32, 1256-1258.	3.9	22
180	Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 920-928.	1.9	22

#	Article	IF	CITATIONS
181	Complex dyskinesias in Parkinson patients on levodopa/carbidopa intestinal gel. Parkinsonism and Related Disorders, 2019, 69, 140-146.	2.2	22
182	Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. Movement Disorders, 2021, 36, 124-132.	3.9	22
183	Changing Gears – <scp>DBS</scp> For Dopaminergic Desensitization in Parkinson's Disease?. Annals of Neurology, 2021, 90, 699-710.	5.3	22
184	Probing responses to deep brain stimulation with functional magnetic resonance imaging. Brain Stimulation, 2022, 15, 683-694.	1.6	22
185	Nigro-striatal involvement in primary progressive freezing gait: Insights into a heterogeneous pathogenesis. Parkinsonism and Related Disorders, 2012, 18, 578-584.	2.2	21
186	Subdural Continuous Theta Burst Stimulation of the Motor Cortex in Essential Tremor. Brain Stimulation, 2015, 8, 840-842.	1.6	21
187	Diagnostic delay in Parkinson's disease caused by PRKN mutations. Parkinsonism and Related Disorders, 2019, 63, 217-220.	2.2	21
188	Continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies. Neurological Sciences, 2019, 40, 1917-1923.	1.9	21
189	Local Field Potential-Based Programming: AÂProof-of-Concept Pilot Study. Neuromodulation, 2022, 25, 271-275.	0.8	21
190	Homotaurine in Parkinson's disease. Neurological Sciences, 2015, 36, 1581-1587.	1.9	20
191	MRI-guided focused ultrasound thalamotomy in fragile X–associated tremor/ataxia syndrome. Neurology, 2016, 87, 736-738.	1.1	20
192	Sequence of electrode implantation and outcome of deep brain stimulation for Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 859-863.	1.9	20
193	Anatomic Targeting of the Optimal Location for Thalamic Deep Brain Stimulation in Patients with Essential Tremor. World Neurosurgery, 2017, 107, 168-174.	1.3	20
194	Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 159-165.	2.2	20
195	Wearable-based mobility monitoring: the long road ahead. Lancet Neurology, The, 2020, 19, 378-379.	10.2	20
196	Sign-specific stimulation â€~hot' and â€~cold' spots in Parkinson's disease validated with machine lea Brain Communications, 2021, 3, fcab027.	rning. 3.9	20
197	Myasthenia gravis: An unrecognized cause of head drop in Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 164-165.	2.2	19
198	Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. Journal of Neurology, 2015, 262, 2539-2547.	3.6	19

#	Article	IF	CITATIONS
199	Dystonia as complication of thalamic neurosurgery. Parkinsonism and Related Disorders, 2019, 66, 232-236.	2.2	19
200	Therapeutic Window of Deep Brain Stimulation Using Cathodic Monopolar, Bipolar, Semi-Bipolar, and Anodic Stimulation. Neuromodulation, 2019, 22, 451-455.	0.8	19
201	Milestones in Tremor Research: 10 Years Later. Movement Disorders Clinical Practice, 2022, 9, 429-435.	1.5	19
202	Tourettism in Multiple Sclerosis: A case report. Journal of the Neurological Sciences, 2009, 287, 288-290.	0.6	18
203	STXBP1 encephalopathy is associated with awake bruxism. Epilepsy and Behavior, 2019, 92, 121-124.	1.7	18
204	Costâ€Effectiveness of Magnetic Resonanceâ€Guided Focused Ultrasound for Essential Tremor. Movement Disorders, 2019, 34, 735-743.	3.9	18
205	Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. Neurology, 2021, 96, e2861-e2873.	1.1	18
206	Telemedicine and Deep brain stimulation - Current practices and recommendations. Parkinsonism and Related Disorders, 2021, 89, 199-205.	2.2	18
207	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.		18
208	Postoperative rehabilitation after deep brain stimulation surgery for movement disorders. Clinical Neurophysiology, 2018, 129, 592-601.	1.5	17
209	Essential tremor: New advances. Clinical Parkinsonism & Related Disorders, 2020, 3, 100031.	0.9	17
210	Punding in Parkinson's disease: The impact of patient's awareness on diagnosis. Movement Disorders, 2010, 25, 1297-1299.	3.9	16
211	Paroxysmal exercise-induced dyskinesia with self-limiting partial epilepsy: A novel GLUT-1Âmutation with benign phenotype. Parkinsonism and Related Disorders, 2011, 17, 479-481.	2.2	16
212	Tactile and Proprioceptive Temporal Discrimination Are Impaired in Functional Tremor. PLoS ONE, 2014, 9, e102328.	2.5	16
213	Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth. Clinical Neuropharmacology, 2014, 37, 91-95.	0.7	16
214	Iron chelation therapy to prevent the manifestations of aceruloplasminemia. Neurology, 2015, 85, 1085-1086.	1.1	16
215	Exploring risk factors for stuttering development in Parkinson disease after deep brain stimulation. Parkinsonism and Related Disorders, 2017, 38, 85-89.	2.2	16
216	When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. Journal of Neurology, 2021, 268, 3203-3211.	3.6	16

#	Article	IF	CITATIONS
217	Nonâ€Motor Fluctuations in Parkinson's Disease: Validation of the Nonâ€Motor Fluctuation Assessment Questionnaire. Movement Disorders, 2021, 36, 1392-1400.	3.9	16
218	Onset and progression of primary torsion dystonia in sporadic and familial cases. European Journal of Neurology, 2006, 13, 1083-1088.	3.3	15
219	Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis. Journal of Neurology, 2007, 254, 113-114.	3.6	15
220	Acute necrotizing encephalopathy: a relapsing case in a European adult. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 227-228.	1.9	15
221	Improvement with Duloxetine in Primary Progressive Freezing Gait. Neurology, 2010, 75, 2130-2132.	1.1	15
222	Aristotle's illusion reveals interdigit functional somatosensory alterations in focal hand dystonia. Brain, 2013, 136, 782-789.	7.6	15
223	Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?. Frontiers in Neurology, 2020, 11, 207.	2.4	15
224	Impaired Temporal Processing of Tactile and Proprioceptive Stimuli in Cerebellar Degeneration. PLoS ONE, 2013, 8, e78628.	2.5	15
225	Experience and consensus on stimulation of the anterior nucleus of thalamus for epilepsy. Epilepsia, 2021, 62, 2883-2898.	5.1	15
226	Task Force Consensus on Nosology and Cutâ€Off Values for Axial Postural Abnormalities in Parkinsonism. Movement Disorders Clinical Practice, 2022, 9, 594-603.	1,5	15
227	Eight-years Failure of Subthalamic Stimulation Rescued by Globus Pallidus Implant. Brain Stimulation, 2014, 7, 179-181.	1.6	14
228	New olfactometric findings in Parkinson's disease. Clinical Otolaryngology, 2017, 42, 837-843.	1.2	14
229	Beyond dystonia and ataxia: Expanding the phenotype of SQSTM1 mutations. Parkinsonism and Related Disorders, 2019, 62, 192-195.	2.2	14
230	Magnetic Resonance-Guided Focused Ultrasound Thalamotomy to Treat Essential Tremor in Nonagenarians. Stereotactic and Functional Neurosurgery, 2020, 98, 182-186.	1.5	14
231	A literature review of magnetic resonance imaging sequence advancements in visualizing functional neurosurgery targets. Journal of Neurosurgery, 2021, 135, 1445-1458.	1.6	14
232	Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape. Brain Stimulation, 2021, 14, 1393-1403.	1.6	14
233	"Masters and servants" in parkinsonian gait: a three-dimensional analysis of biomechanical changes sensitive to disease progression. Functional Neurology, 2014, 29, 99-105.	1.3	14
234	Full Parkinsonian Triad Induced by Pallidal Highâ€Frequency Stimulation in Cervical Dystonia. Movement Disorders Clinical Practice, 2015, 2, 99-101.	1.5	13

#	Article	IF	CITATIONS
235	Pedunculopontine Nucleus Stimulation in Parkinson's Disease Dementia. Biological Psychiatry, 2015, 77, e35-e40.	1.3	13
236	Split-arm swinging: the effect of arm swinging manipulation on interlimb coordination during walking. Journal of Neurophysiology, 2017, 118, 1021-1033.	1.8	13
237	Cervical dystonia patients display subclinical gait changes. Parkinsonism and Related Disorders, 2017, 43, 97-100.	2.2	13
238	A prospective evaluation of taste in Parkinson's disease. Journal of Neural Transmission, 2017, 124, 347-352.	2.8	13
239	Levodopaâ€carbidopa intestinal gel therapy after deep brain stimulation. Movement Disorders, 2018, 33, 334-335.	3.9	13
240	Patient-adjusted deep-brain stimulation programming is time saving in dystonia patients. Journal of Neurology, 2019, 266, 2423-2429.	3.6	13
241	Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study. Journal of Neurology, 2020, 267, 2556-2566.	3.6	13
242	Action Myoclonus and Seizure in Kuforâ€Rakeb Syndrome. Movement Disorders Clinical Practice, 2018, 5, 195-199.	1.5	13
243	Dystonia gravidarum: A new case with a long follow-up. Movement Disorders, 2007, 22, 564-566.	3.9	12
244	Safety and Efficacy of Rotigotine in Individuals with <scp>P</scp> arkinson's Disease Aged 75 and Older. Journal of the American Geriatrics Society, 2011, 59, 2386-2387.	2.6	12
245	Current or voltage? Another Shakespearean dilemma. European Journal of Neurology, 2015, 22, 887-888.	3.3	12
246	Subthalamic Nucleus Visualization on Routine Clinical Preoperative MRI Scans: A Retrospective Study of Clinical and Image Characteristics Predicting Its Visualization. Stereotactic and Functional Neurosurgery, 2018, 96, 120-126.	1.5	12
247	Sleepâ€related motor and behavioral disorders: Recent advances and new entities. Movement Disorders, 2018, 33, 1042-1055.	3.9	12
248	Implementation of the Current Dystonia Classification from 2013 to 2018. Movement Disorders Clinical Practice, 2019, 6, 250-253.	1.5	12
249	Ultraâ€highâ€frequency deep brain stimulation at 10,000 Hz improves motor function. Movement Disorders, 2019, 34, 146-148.	3.9	12
250	Sleep disturbance in movement disorders: insights, treatments and challenges. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 723-736.	1.9	12
251	Acute low frequency dorsal subthalamic nucleus stimulation improves verbal fluency in Parkinson's disease. Brain Stimulation, 2021, 14, 754-760.	1.6	12
252	Is punding a stereotypy?. Movement Disorders, 2013, 28, 404-405.	3.9	11

#	Article	IF	CITATIONS
253	Reliability of Clinical Diagnosis of Dystonia. Neuroepidemiology, 2014, 43, 213-219.	2.3	11
254	Spinal cord stimulation in primary progressive freezing of gait. Movement Disorders, 2017, 32, 1336-1337.	3.9	11
255	Pisa syndrome in Parkinsonzs disease: electromyographic quantification of paraspinal and non-paraspinal muscle activity. Functional Neurology, 2017, 37, 143.	1.3	11
256	Aggressiveness after centromedian nucleus stimulation engages prefrontal thalamocortical circuitry. Brain Stimulation, 2020, 13, 357-359.	1.6	11
257	Association Between Cerebrospinal Fluid Biomarkers and Age-related Brain Changes in Patients with Normal Pressure Hydrocephalus. Scientific Reports, 2020, 10, 9106.	3.3	11
258	Parkinson's Disease and <scp>COVID</scp> â€19: Do We Need to Be More Patient?. Movement Disorders, 2021, 36, 277-277.	3.9	11
259	Bacterial infections: small intestine and colon. Current Opinion in Gastroenterology, 2001, 17, 4-9.	2.3	10
260	Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: An outpatient model. Movement Disorders, 2015, 30, 598-599.	3.9	10
261	How much does sex matter in Parkinson disease?. Neurology, 2015, 84, 2102-2104.	1.1	10
262	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. Movement Disorders Clinical Practice, 2016, 3, 184-187.	1.5	10
263	Hybrid deep brain stimulation system to manage stimulation-induced side effects in essential tremor patients. Parkinsonism and Related Disorders, 2019, 58, 85-86.	2.2	10
264	The Child & Youth CompreHensIve Longitudinal Database for Deep Brain Stimulation (CHILD-DBS). Child's Nervous System, 2021, 37, 607-615.	1.1	10
265	Mapping efficacious deep brain stimulation for pediatric dystonia. Journal of Neurosurgery: Pediatrics, 2021, 27, 346-356.	1.3	10
266	<scp>Singleâ€Trajectory Multipleâ€Target</scp> Deep Brain Stimulation for Parkinsonian Mobility and Cognition. Movement Disorders, 2022, 37, 635-640.	3.9	10
267	Deep brain stimulation for extreme behaviors associated with autism spectrum disorder converges on a common pathway: a systematic review and connectomic analysis. Journal of Neurosurgery, 2022, , 1-10.	1.6	10
268	Progressive Worsening of Gait and Motor Abnormalities in Older Adults With Dravet Syndrome. Neurology, 2022, 98, .	1.1	10
269	Olfactory impairment and pathology in neurodegenerative disorders with brain iron accumulation. Acta Neuropathologica, 2013, 126, 151-153.	7.7	9
270	Does dominant pedunculopontine nucleus exist?. Brain, 2015, 138, e323-e323.	7.6	9

#	Article	IF	CITATIONS
271	Basal ganglia calcification in a case of PKAN. Parkinsonism and Related Disorders, 2017, 36, 98-99.	2.2	9
272	Functional movement disorders arising after successful deep brain stimulation. Neurology, 2018, 90, 931-932.	1.1	9
273	Pisa syndrome in Idiopathic Normal Pressure Hydrocephalus. Parkinsonism and Related Disorders, 2019, 66, 40-44.	2.2	9
274	Use of AbobotulinumtoxinA in Adults with Cervical Dystonia: A Systematic Literature Review. Toxins, 2020, 12, 470.	3.4	9
275	Characterizing Advanced Parkinson's Disease: Romanian Subanalysis from the OBSERVE-PD Study. Parkinson's Disease, 2021, 2021, 1-12.	1.1	9
276	Health care of children living with their mother in prison compared with the general population. Scandinavian Journal of Public Health, 2009, 37, 265-272.	2.3	8
277	Rare and serious cardiac side effects during ropinirole titration. Movement Disorders, 2010, 25, 1509-1510.	3.9	8
278	Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?. Journal of Neural Transmission, 2012, 119, 597-604.	2.8	8
279	Congenital Mirror Movements in a New Italian Family. Movement Disorders Clinical Practice, 2014, 1, 180-187.	1.5	8
280	Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada. Canadian Journal of Neurological Sciences, 2017, 44, 132-138.	0.5	8
281	Management of Pisa syndrome with lateralized subthalamic stimulation. Journal of Neurology, 2018, 265, 2442-2444.	3.6	8
282	Medical management of myoclonus-dystonia and implications for underlying pathophysiology. Parkinsonism and Related Disorders, 2020, 77, 48-56.	2.2	8
283	Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease. Movement Disorders, 2021, 36, 672-680.	3.9	8
284	Theta Burst Deep Brain Stimulation in Movement Disorders. Movement Disorders Clinical Practice, 2021, 8, 282-285.	1.5	8
285	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. Canadian Journal of Neurological Sciences, 2022, 49, 19-28.	0.5	8
286	Programming Directional Deep Brain Stimulation in Parkinson's Disease: A Randomized Prospective Trial Comparing Early versus Delayed Stimulation Steering. Stereotactic and Functional Neurosurgery, 2021, 99, 484-490.	1.5	8
287	Neural Correlates of Optimal Deep Brain Stimulation for Cervical Dystonia. Annals of Neurology, 2022, 92, 418-424.	5.3	8
288	Patients and DBS targets: Is there any rationale for selecting them?. Basal Ganglia, 2012, 2, 211-219.	0.3	7

#	Article	IF	CITATIONS
289	Ticâ€induced gait dysfunction. Movement Disorders, 2012, 27, 911-912.	3.9	7
290	Xeomin®use in patients with systemic immune reactions to other botulinum toxins type A. European Journal of Neurology, 2013, 20, e45-e46.	3.3	7
291	Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease. Movement Disorders, 2015, 30, 1859-1860.	3.9	7
292	Dopamine dysregulation syndrome with psychosis in 24-hourÂintestinal levodopa infusion for Parkinson's disease. Parkinsonism and Related Disorders, 2016, 28, 152-154.	2.2	7
293	SCA 35 presenting as isolated treatment-resistant dystonic hand tremor. Parkinsonism and Related Disorders, 2017, 37, 118-119.	2.2	7
294	Extradural motor cortex stimulation improves gait, speech, and language in a patient with pure akinesia. Brain Stimulation, 2018, 11, 1192-1194.	1.6	7
295	Pantothenate kinase-associated neurodegeneration mimicking Tourette syndrome: a case report and review of the literature. Neurological Sciences, 2018, 39, 1797-1800.	1.9	7
296	The clinical significance of lower limb tremors. Parkinsonism and Related Disorders, 2019, 65, 165-171.	2.2	7
297	Movement disorders phenomenology in focal motor seizures. Parkinsonism and Related Disorders, 2019, 61, 161-165.	2.2	7
298	Generalized Dystonia and Paroxysmal Dystonic Attacks due to a Novel Variant. Tremor and Other Hyperkinetic Movements, 2019, 9, .	2.0	7
299	Two indications, one target: Concomitant epilepsy and Tourettism treated with Centromedian/parafascicular thalamic stimulation. Brain Stimulation, 2017, 10, 711-713.	1.6	6
300	Hepatitis C Virus–Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report. Annals of Internal Medicine, 2017, 166, 379.	3.9	6
301	Enteral feeding in Parkinson's patients receiving levodopa/carbidopa intestinal gel. Parkinsonism and Related Disorders, 2017, 42, 109-111.	2.2	6
302	Brain injury due to head banging in Tourette. Parkinsonism and Related Disorders, 2018, 49, 114-115.	2.2	6
303	When shaking during standing points to hereditary spastic paraplegias. Parkinsonism and Related Disorders, 2018, 46, 92-94.	2.2	6
304	Isolated gait dysfunction due to intracranial hypotension. Neurology, 2018, 91, 271-273.	1.1	6
305	Deep brain stimulation in status dystonicus caused by anti-NMDA receptor encephalitis. Parkinsonism and Related Disorders, 2019, 66, 255-257.	2.2	6
306	Unusual gait disorders: a phenomenological approach and classification. Expert Review of Neurotherapeutics, 2019, 19, 119-132.	2.8	6

#	Article	IF	CITATIONS
307	Beta-propeller protein associated neurodegeneration (BPAN); the first report of three patients from Iran with de novo novel mutations. Parkinsonism and Related Disorders, 2019, 61, 231-233.	2.2	6
308	Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. Brain Sciences, 2021, 11, 416.	2.3	6
309	Self-adjustment of deep brain stimulation delays optimization in Parkinson's disease. Brain Stimulation, 2021, 14, 676-681.	1.6	6
310	Flexible vs. standard subthalamic stimulation in Parkinson disease: A double-blind proof-of-concept cross-over trial. Parkinsonism and Related Disorders, 2021, 89, 93-97.	2.2	6
311	Parkinsonism and cerebrospinal fluid disorders. Journal of the Neurological Sciences, 2022, 433, 120019.	0.6	6
312	Safety assessment of spine MRI in deep brain stimulation patients. Journal of Neurosurgery: Spine, 2020, 32, 973-983.	1.7	6
313	Characterizing Orthostatic Tremor Using a Smartphone Application. Tremor and Other Hyperkinetic Movements, 2017, 7, 488.	2.0	6
314	Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. Movement Disorders Clinical Practice, 2022, 9, 522-529.	1.5	6
315	Parkinsonism in idiopathic normal pressure hydrocephalus: is it time for defining a clinical tetrad?. Neurological Sciences, 2022, 43, 5201-5205.	1.9	6
316	Increased excretion of glycosaminoglycans in children with urinary incontinence compared to those with monosymptomatic nocturnal enuresis. Scandinavian Journal of Urology and Nephrology, 2007, 41, 218-222.	1.4	5
317	Methcathinoneâ€induced parkinsonism results from permanent brain damage: a message for the masses. European Journal of Neurology, 2014, 21, 181-182.	3.3	5
318	Graftâ€induced dyskinesias fail to respond to 5HT _{1A} agonist in the longâ€ŧerm. Movement Disorders, 2015, 30, 872-873.	3.9	5
319	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. Movement Disorders Clinical Practice, 2017, 4, 772-774.	1.5	5
320	SCL20A2 mutation mimicking fluctuating Parkinson's disease. Parkinsonism and Related Disorders, 2017, 39, 93-94.	2.2	5
321	Tongue Protrusion Dystonia in Pantothenate Kinase-Associated Neurodegeneration. Pediatric Neurology, 2020, 103, 76-78.	2.1	5
322	TNR Gene Mutation in Familial Parkinson's Disease: Possible Implications for Essential Tremor. Journal of Movement Disorders, 2021, 14, 170-172.	1.3	5
323	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. Journal of Parkinson's Disease, 2022, 12, 117-128.	2.8	5
324	Neurologic aspects and falls. Clinical Cases in Mineral and Bone Metabolism, 2012, 9, 17-20.	1.0	5

#	Article	IF	CITATIONS
325	An open-label prospective pilot trial of nucleus accumbens deep brain stimulation for children with autism spectrum disorder and severe, refractory self-injurious behavior: study protocol. Pilot and Feasibility Studies, 2022, 8, 24.	1.2	5
326	Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial. Movement Disorders, 2022, , .	3.9	5
327	Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson's Disease-Related Pill Burden Reduction in Advanced Parkinson's Disease: A Retrospective Real-World Cohort Study. Neurology and Therapy, 2022, 11, 851-861.	3.2	5
328	Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT. Nuclear Medicine Communications, 2012, 33, 933-940.	1.1	4
329	Punding Behavior in Bipolar Disorder Type 1: Case Report. Journal of Neuropsychiatry and Clinical Neurosciences, 2014, 26, E8-E9.	1.8	4
330	Future Scenarios for Levodopa-Induced Dyskinesias in Parkinsonââ,¬â"¢s Disease. Frontiers in Neurology, 2015, 6, 76.	2.4	4
331	Acetazolamide-induced myokymia. Parkinsonism and Related Disorders, 2015, 21, 542-543.	2.2	4
332	Management of aripiprazole-induced tardive Pisa syndrome. International Clinical Psychopharmacology, 2016, 31, 57-60.	1.7	4
333	A 21‥ear Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. Movement Disorders, 2018, 33, 850-852.	3.9	4
334	Cerebral peri-lead edema following deep brain stimulation surgery. Neurological Sciences, 2020, 41, 473-475.	1.9	4
335	Status dystonicus induced by deep brain stimulation surgery. Neurological Sciences, 2020, 41, 729-730.	1.9	4
336	Novel Deep Brain Stimulation Technologies for Parkinson's Disease: More Expectations, More Frustrations?. Movement Disorders Clinical Practice, 2020, 7, 113-114.	1.5	4
337	Treatment of Dystonia Using Trihexyphenidyl in Costello Syndrome. Brain Sciences, 2020, 10, 450.	2.3	4
338	Normal Pressure Hydrocephalus in Down Syndrome: The Report of Two Cases. Journal of Alzheimer's Disease, 2020, 77, 979-984.	2.6	4
339	Surgical Management of Parkinson's Disease in the Elderly. Movement Disorders Clinical Practice, 2021, 8, 500-509.	1.5	4
340	βâ€Blocker–Induced Tremor. Movement Disorders Clinical Practice, 2021, 8, 449-452.	1.5	4
341	Multiculturalism: A Challenge for Cognitive Screeners in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 733-742.	1.5	4
342	The Most Cited Works in Essential Tremor and Dystonia. Tremor and Other Hyperkinetic Movements, 2016, 6, 310.	2.0	4

#	Article	IF	CITATIONS
343	The six gaps in the search of neuroprotection for Parkinson's disease. Expert Review of Neurotherapeutics, 2012, 12, 111-113.	2.8	3
344	Flamenco dancer posture. Neurology, 2016, 86, 1462-1463.	1.1	3
345	Unvoluntary Motor Behaviours. , 2016, , 97-153.		3
346	Thalamic deep brain stimulation and gait in orthostatic tremor. Movement Disorders, 2017, 32, 937-938.	3.9	3
347	Dopamine agonist withdrawal syndrome in Parkinson's disease. Journal of the Neurological Sciences, 2017, 382, 47-48.	0.6	3
348	Cerebrospinal Fluid Biomarkers and Normal Pressure Hydrocephalus: A Perfect Duo?. Canadian Journal of Neurological Sciences, 2018, 45, 1-2.	0.5	3
349	Stimulation-induced reversed plus-minus syndrome: Insights into eyelidÂphysiology. Brain Stimulation, 2018, 11, 951-952.	1.6	3
350	Single-pulse subthalamic deep brain stimulation reduces premotor-motor facilitation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 224-227.	2.2	3
351	CSF leak leading to seroma formation. Postgraduate Medical Journal, 2019, 95, 176-176.	1.8	3
352	Lateâ€Onset Mitochondrial Membrane Protein–Associated Neurodegeneration With Extensive Brain Iron Deposition. Movement Disorders Clinical Practice, 2020, 7, 120-121.	1.5	3
353	Fading of Deep Brain Stimulation Efficacy Versus Disease Progression: Untangling a Gordian Knot. Movement Disorders Clinical Practice, 2020, 7, 747-749.	1.5	3
354	Microelectrode Recording and Radiofrequency Thalamotomy following Focused Ultrasound Thalamotomy. Stereotactic and Functional Neurosurgery, 2021, 99, 34-37.	1.5	3
355	Functional Dyskinesias following Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Report of Three Cases. Movement Disorders Clinical Practice, 2021, 8, 114-117.	1.5	3
356	Basic Tips: How Do I Start Programming Deep Brain Stimulation in Parkinson Disease Patients?. Movement Disorders Clinical Practice, 2021, 8, 639-644.	1.5	3
357	Subthalamic Nucleus Deep Brain Stimulation as Rescue Therapy for Levodopa Carbidopa Intestinal Gel–Associated Biphasic‣ike Dyskinesias. Movement Disorders Clinical Practice, 2021, 8, 1155-1156.	1.5	3
358	Modulation of CNS Functions by Deep Brain Stimulation: Insights Provided byÂMolecular Imaging. , 2021, , 1177-1244.		3
359	Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital. International Review of Neurobiology, 2022, , .	2.0	3
360	Functional tremor developing after successful MRI-guided focused ultrasound thalamotomy for essential tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 625-627.	1.9	3

#	Article	IF	CITATIONS
361	Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the <scp>OBSERVEâ€PD</scp> observational study. Acta Neurologica Scandinavica, 2022, 146, 167-176.	2.1	3
362	A Functional Connectome of Parkinson's Disease Patients Prior to Deep Brain Stimulation: A Tool for Disease-Specific Connectivity Analyses. Frontiers in Neuroscience, 0, 16, .	2.8	3
363	Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for longâ€ŧerm clinical trials. Movement Disorders, 2011, 26, 1370-1370.	3.9	2
364	Lowâ€Frequency Stimulation of Globus Pallidus Internus for Axial Motor Symptoms of Parkinson's Disease. Movement Disorders Clinical Practice, 2015, 2, 445-446.	1.5	2
365	Central conduction abnormalities in patients receiving levodopa-carbidopa intestinal gel infusion. Neurological Sciences, 2017, 38, 1869-1872.	1.9	2
366	Multiple sclerosis tremor: are technical advances enough?. Lancet Neurology, The, 2017, 16, 678-679.	10.2	2
367	Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Lowâ€frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?― Movement Disorders, 2017, 32, 176-177.	3.9	2
368	Letter in response to "Rethinking status dystonicus — A welcome start to a challenging problem― Movement Disorders, 2018, 33, 345-345.	3.9	2
369	αâ€ S ynuclein strains in multiple system atrophy: A product of their environment?. Movement Disorders, 2018, 33, 1270-1270.	3.9	2
370	Functional eyelid opening apraxia: a kinematic study. European Journal of Neurology, 2018, 25, e95-e97.	3.3	2
371	Jumping to overcome freezing of gait while turning in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 349-351.	2.2	2
372	Pediatric freezing of gait caused by antiâ€NMDAR encephalitis. Movement Disorders, 2019, 34, 756-757.	3.9	2
373	Reply to: Standardized 25â€Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVIDâ€19. Movement Disorders, 2020, 35, 1498-1498.	3.9	2
374	Excessive Cerebellar Oscillations in Essential Tremor: Insights Into Disease Mechanism and Treatment. Movement Disorders, 2020, 35, 758-758.	3.9	2
375	Constant Current versus Constant Voltage: Clinical Evidence Supporting a Fundamental Difference in the Modalities. Stereotactic and Functional Neurosurgery, 2021, 99, 171-175.	1.5	2
376	Reply to: "Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus― Movement Disorders, 2021, 36, 1043-1044.	3.9	2
377	Whole-Genome Study of a Multigenerational Family with Essential Tremor. Canadian Journal of Neurological Sciences, 2021, , 1-6.	0.5	2
378	Coexistence of deep brain stimulators and cardiac implantable electronic devices: A systematic review of safety. Parkinsonism and Related Disorders, 2021, 88, 129-135.	2.2	2

#	Article	IF	CITATIONS
379	Commentary: Paraneoplastic Syndrome Associated with Kelchâ€Like Protein 11 Antibodies Presenting with Progressive Ataxia and Tremor. Movement Disorders Clinical Practice, 2021, 8, S45-S46.	1.5	2
380	Developmental and Epileptic Encephalopathies in Adults. Neurology, 2022, 99, 89-91.	1.1	2
381	The diagnostic importance of the isolated supranuclear downward gaze ophthalmoplegia in progressive supranuclear palsy. Neurological Sciences, 2003, 24, 161-161.	1.9	1
382	Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering. , 2009, , 112-130.		1
383	Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT study: reply to comment by Erro et al European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 638-639.	6.4	1
384	Reply: The FM/AM world is shaping the future of deep brain stimulation. Movement Disorders, 2014, 29, 1327-1328.	3.9	1
385	Response to: Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease. Parkinsonism and Related Disorders, 2016, 31, 143.	2.2	1
386	Rhythmical Involuntary Movements (Tremor and Tremor-Like Conditions). , 2016, , 207-263.		1
387	Tetrabenazine and subthalamic stimulation in graft-induced dyskinesias. Neurology, 2017, 89, 1305-1306.	1.1	1
388	Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: what's in a phenotype?. Journal of the Neurological Sciences, 2018, 390, 84-86.	0.6	1
389	Deep brain stimulation in cerebral palsy: Time for dynamism in a static encephalopathy. European Journal of Paediatric Neurology, 2018, 22, 221-222.	1.6	1
390	Gelastic Cataplexy in Niemann Pick Type C. Movement Disorders Clinical Practice, 2019, 6, 498-499.	1.5	1
391	Childhood choreoathetosis secondary to hyper-IgM syndrome (CD40 ligand deficiency). Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e899.	6.0	1
392	Seizures in Hereditary Aceruloplasminemia. Canadian Journal of Neurological Sciences, 2021, 48, 144-147.	0.5	1
393	Probabilistic characterisation of deep brain stimulation in patients with tardive syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 909-911.	1.9	1
394	Advanced Therapies for the Management of Dopamine Dysregulation Syndrome in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 400-405.	1.5	1
395	Corpus Callosum Hyperintensity in Normal Pressure Hydrocephalus After Ventriculoperitoneal Shunt. Neurology, 2021, 96, 1096-1097.	1.1	1
396	Factors Influencing the Surgical Decision in Dystonia Patients Referred for Deep Brain Stimulation. Toxins, 2021, 13, 511.	3.4	1

#	Article	IF	CITATIONS
397	Recognizing J. Purdon Martin's Contribution to Our Understanding of Locomotion and Basal Ganglia. Movement Disorders Clinical Practice, 2022, 9, 326-329.	1.5	1
398	Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. , 2018, 265, 2211.		1
399	Status Dystonicus. Current Clinical Neurology, 2022, , 183-199.	0.2	1
400	Identical twins with progressive kyphoscoliosis and ophthalmoplegia. Parkinsonism and Related Disorders, 2021, 92, 119-122.	2.2	1
401	Severe jaw-opening off-dystonia in Parkinson's disease masked by effective deep brain stimulation of the subthalamic nucleus. Neurological Sciences, 2022, 43, 1449-1450.	1.9	1
402	Commentary: Feasibility of Magnetic Resonance–Guided Focused Ultrasound Thalamotomy for Essential Tremor in the Setting of Prior Craniotomy. Operative Neurosurgery, 2022, Publish Ahead of Print, .	0.8	1
403	Dysgeusia induced and resolved by focused ultrasound thalamotomy: case report. Journal of Neurosurgery, 2022, 136, 215-220.	1.6	1
404	An unusual case of deep brain stimulation-induced insomnia. Sleep Medicine, 2022, 89, 156-158.	1.6	1
405	Effect of Public Interest in Magnetic Resonance Imaging–Guided Focused Ultrasound on Enrolment for Deep Brain Stimulation. Movement Disorders, 2022, 37, 1103-1104.	3.9	1
406	Functional Neurological Disorders and COVID-19 Vaccine: A Call for Action. Canadian Journal of Neurological Sciences, 2023, 50, 325-326.	0.5	1
407	Functional Patients Referred for Deep Brain Stimulation: How Common is it?. Movement Disorders Clinical Practice, 0, , .	1.5	1
408	FC12-04 - Striatal dopamine transporter (DAT) availability and affective symptoms in movement disorders: A 123I-FP-CIT spect study. European Psychiatry, 2011, 26, 1879-1879.	0.2	0
409	Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation. Current Treatment Options in Neurology, 2013, 15, 583-592.	1.8	Ο
410	Malevich's Shoulder and Dystonia. Movement Disorders Clinical Practice, 2014, 1, 273-273.	1.5	0
411	Axial Disorders of Movement. , 2016, , 361-435.		0
412	Tremor with congenital mirror movements: evidence of involvement of the primary motor cortex in tremor. European Journal of Neurology, 2019, 26, e66-e67.	3.3	0
413	Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?― Movement Disorders, 2020, 35, 1883-1883.	3.9	0
414	Tremor: so common, so difficult. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 809-810.	1.9	0

#	Article	IF	CITATIONS
415	Neuronal Activity and Synaptic Plasticity in a Reimplanted STN-DBS Patient with Parkinson's Disease: Recordings from Two Surgeries. Stereotactic and Functional Neurosurgery, 2020, 98, 206-212.	1.5	0
416	From vision to action: Canadian leadership in ethics and neurotechnology. International Review of Neurobiology, 2021, 159, 241-273.	2.0	0
417	<scp><i>VPS16</i></scp> and <scp><i>VPS41</i></scp> : The List of Genes Causing Earlyâ€Onset Dystonia Keeps Expanding. Movement Disorders, 2021, 36, 609-609.	3.9	0
418	Mind over motor. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 573-573.	1.9	0
419	Motor blocks during bilateral stepping in Parkinson's disease and effects of dopaminergic medication. Parkinsonism and Related Disorders, 2021, 85, 1-4.	2.2	0
420	Commentary: Juvenile Dystoniaâ€Parkinsonism due to <scp><i>DNAJC6</i></scp> Mutation. Movement Disorders Clinical Practice, 2021, 8, S29-S31.	1.5	0
421	Bing-Neel Syndrome. Neurology, 2021, 97, 1033-1034.	1.1	0
422	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
423	Patterned or Repetitive Movements and/or Abnormal Posturing. , 2016, , 265-303.		0
424	Punding (PD)â~†., 2017,,.		0
425	Tremor. , 2020, , 193-215.		0
426	Gait Impairment in Myoclonus-Dystonia (DYT-). Tremor and Other Hyperkinetic Movements, 2019, 9, .	2.0	0
427	Focused Ultrasound Thalamotomy Sensory Side Effects Follow the Thalamic Structural Homunculus. Neurology: Clinical Practice, 2021, 11, e497-e503.	1.6	0
428	Editorial on the Special Issue "Botulinum Toxin for the Treatment of Neurological Disorders: Where We Are and Where We Need to Go― Toxins, 2022, 14, 41.	3.4	0
429	Seizure in Neurodegeneration with brain iron accumulation: A Systematic Review. Canadian Journal of Neurological Sciences, 2022, , 1-29.	0.5	0
430	Are we on the right track in tracking tics?. Clinical Neurophysiology, 2022, 134, 100-101.	1.5	0
431	Conditions associated with <scp>ON</scp> â€state freezing of gait. Movement Disorders Clinical Practice, 2022, 9, 558-559.	1.5	0
432	A Cautionary Tale of Magnetic Resonanceâ€Guided Focused Ultrasound Thalamotomyâ€Induced White Matter Lesions. Movement Disorders, 2022, 37, 1953-1955.	3.9	0

#	Article	IF	CITATIONS
433	Healthcare Differences and <scp>COVID</scp> â€19 impact on Parkinson's disease. Movement Disorders Clinical Practice, 0, , .	1.5	0